WuXi Biologics Tops Sustainable Biopharma List, Highlighting Green CRDMO Strategy
Event summary
- WuXi Biologics recognized in BioPharma APAC's Top 26 Sustainable Biopharma Practices 2026 for its Green CRDMO solutions.
- Company's Green CRDMO integrates sustainability into research, development, manufacturing, and operations.
- WuXi Biologics aims for net-zero emissions across its value chain by 2050, with SBTi-validated targets.
- Green manufacturing solutions reduce water use by 70%, resource use by 33%, and climate impacts by 40% compared to traditional methods.
- Company has received multiple ESG recognitions, including MSCI AAA rating, EcoVadis Platinum Medal, and inclusion in Dow Jones sustainability indices.
The big picture
WuXi Biologics' recognition underscores the growing importance of sustainability in the biopharmaceutical industry. As climate change and resource efficiency become core focus areas, companies are increasingly expected to set science-based climate targets and reduce Scope 3 emissions. WuXi Biologics' Green CRDMO strategy positions it as a leader in translating sustainability into business value, helping clients enhance governance, reduce costs, and improve supply-chain resilience. The company's commitment to net-zero emissions by 2050 and its receipt of multiple ESG recognitions highlight its strategic priority in creating shared sustainable value across the value chain.
What we're watching
- Sustainability Leadership
- Whether WuXi Biologics can maintain its position as a leader in sustainable biopharma practices amid increasing industry competition.
- Regulatory Compliance
- The pace at which global green procurement requirements and ESG disclosures will impact WuXi Biologics' operations and client relationships.
- Technological Innovation
- How WuXi Biologics' advancements in green technology will affect its ability to reduce lifecycle environmental impacts and improve operational efficiency.